Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
Fund Manager Portfolios
Gain insights from the world's largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Search
Sign in
Sign up
Kiora Pharmaceuticals
KPRX
Market cap
$9.24M
Overview
Fund Trends
Analyst Outlook
Journalist POV
2.69
USD
--0.03
1.1%
At close
Updated
Oct 16, 12:15 PM EDT
Pre-market
After hours
1D
5D
1M
3M
6M
YTD
1Y
5Y
10Y
1 day
-1.1%
5 days
-4.61%
1 month
1.51%
3 months
-14.6%
6 months
-2.18%
Year to date
-24.86%
1 year
-20.88%
5 years
-99.8%
10 years
-99.99%
Positive
Neutral
Negative
Sentiment
3-Months
Positive
Neutral
80%
Negative
Positive
Neutral
Negative
Neutral
Newsfile Corp
yesterday
Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025
Encinitas, California--(Newsfile Corp. - October 15, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an ophthalmology panel at the upcoming 2025 Maxim Growth Summit in New York and give an overview of its development pipeline at Eyecelerator @ AAO 2025 in Orlando. Maxim Growth Summit Ophthalmology Panel Details Title: A vision of innovation; Advances in biotechnology have spurred innovation in the management of diseases affecting our most used sense Presenter: Brian M.
Neutral
The Motley Fool
2 months ago
Kiora (KPRX) Q2 Revenue Falls 100%
Kiora (KPRX) Q2 Revenue Falls 100%
Neutral
Newsfile Corp
2 months ago
Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases
Encinitas, California--(Newsfile Corp. - August 8, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced second quarter 2025 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key second quarter and 2025 year-to-date corporate highlights include: KIO-104 Initiated KLARITY, a Phase 2 clinical trial evaluating KIO-104 for the treatment of patients with retinal inflammation.
Neutral
Newsfile Corp
2 months ago
Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease
Encinitas, California--(Newsfile Corp. - July 22, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced it has received a patent (US Patent No. 12,364,680) covering KIO-104 for the treatment of a wide range of ocular diseases.
Positive
Zacks Investment Research
3 months ago
Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know
Kiora Pharmaceuticals (KPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
Newsfile Corp
4 months ago
Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia
Total potential deal value of $110 million plus royalties Kiora to receive an immediate $1.25 million exclusive option fee If the option is exercised, Kiora will receive an additional mid-single digit million up-front payment, development, regulatory, and commercial milestones, plus tiered royalties on sales Encinitas, California--(Newsfile Corp. - June 3, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it has granted Senju Pharmaceutical Co., Ltd. (Senju) an exclusive option to exercise rights to an exclusive development and commercialization agreement for KIO-301 for the treatment of ophthalmic diseases.
Neutral
Newsfile Corp
5 months ago
Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027
Encinitas, California--(Newsfile Corp. - May 9, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced first quarter 2025 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key first quarter and 2025 year-to-date corporate highlights include: Received approval to initiate KLARITY, a Phase 2 clinical trial evaluating KIO-104 for the treatment of retinal inflammation.
Neutral
Newsfile Corp
6 months ago
Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference
Ecinitas, California--(Newsfile Corp. - April 4, 2025) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, 2025, at 2:15 pm EDT. President & CEO, Brian M.
Neutral
Newsfile Corp
6 months ago
Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027
Encinitas, California--(Newsfile Corp. - March 25, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its 2024 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key fourth quarter and 2025 year-to-date corporate highlights include: Received approval to initiate KLARITY, a Phase 2 trial of KIO-104 for the treatment retinal inflammation.
Neutral
Newsfile Corp
7 months ago
Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting
Encinitas, California--(Newsfile Corp. - March 12, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced their abstract of a preclinical study of KIO-104 in a proliferative vitreoretinopathy (PVR) model was accepted for poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, UT, May 4-8, 2025. The findings support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.
Show more
See News Rankings
Sign up
Sign in
Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
Fund Manager Portfolios
Gain insights from the world's largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Theme
Close